Collaboration Produces New PD-L1 Antibody for Immuno-Oncology Research
Jul 03 2018 Read 400 Times
Abcam have announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.
Developed by Abcam for use by Merck as an analytical antibody to support Merck’s therapeutic programme several years ago, this new clone has been created by Abcam’s in-house antibody engineers, who specialise in the discovery and development of challenging antibodies. The antibody is important in assessing the expression of PD-L1 in tumours from patients who might be able to benefit from PD-1/PD-L1 checkpoint immunotherapy.
John Baker, SVP Portfolio and Business Development, Abcam said: “Collaborations with industry partners are an important part of Abcam’s strategy to provide the best tools to all researchers world-wide. By working with Merck we are able to make available this important antibody at scale to help scientists accelerate their research, and expand understanding of the role of immune checkpoint inhibitors as cancer therapeutics.”
Clone 73-10 is an important addition to Abcam’s range of PD-1/PD-L1 immune checkpoint antibodies and is available via the Abcam website. To find out more please visit www.abcam.com/pdl1-ab-73-10.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Mass Spectrometry & Spectroscopy - 67th ASMS Conference on Mass Spectrometry and Allied Topics - Modular MS Bench System with Integrated Gas Supply for Sciex LC-MS/MS Unveile...
View all digital editions
Aug 04 2019 Anaheim, CA, USA
Aug 04 2019 Portland, OR, USA
Aug 05 2019 Lombard, IL, USA
Aug 25 2019 San Diego, CA, USA
Sep 01 2019 Berlin, Germany